DUBLIN--(BUSINESS WIRE)--The "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Indonesia" report has been added to Research and Markets' offering.
Indonesian pharmaceutical market increased from US$3.13 Billion in 2009 to US$6.20 Billion in 2016, at a Compound Annual Growth Rate (CAGR) of 10.3%. The market value is expected to reach US$10.11 Billion in 2021.
The growth of the Indonesian pharmaceutical sector is largely driven by the Universal Health Coverage scheme (Jaminan Kesehatan Nasional, JKN), which prioritizes the use of generics. Despite increasing sales of unbranded generics, the sector is witnessing a growing number of new players, which drive price competition and reduce margins. In 2015, the unbranded generic market represented a 10.8% of the pharmaceutical market.
In 2015, the pharmaceutical-sales-to-GDP ratio shrank to 0.57%, despite pharmaceutical sales increasing from US$6.18 Billion in the previous year to US$6.89 Billion. Pharmaceutical sales per capita increased from US$24.5 Billion in 2014 to US$26.9 Billion in 2015. The pharmaceutical-sales-to-health-spending ratio dropped from US$21.4 Billion in 2014 to US$20.5 Billion in 2015. Non-communicable diseases cost the economy US$7 Billion between 2011 and 2015 in treatment and loss of productivity.
Medical device market of Indonesia was worth US$2.28 Billion in 2016, and is expected to reach US$2.83 Billion in 2017 and US$3.54 Billion in 2018. Indonesia manufactures hospital beds, disposable supplies and wheelchairs, but imports more than 90% of its medical devices, as the domestic industry is under-developed.
Key Topics Covered:
1 Table of Contents
2 Executive Summary
4 Overview of the Pharmaceutical and Medical Device Markets
5 Market Access
6 Country Analysis
7 Opportunities and Challenges
For more information about this report visit https://www.researchandmarkets.com/research/6qwqzp/countryfocus